AmDen Pharmaceuticals Denmark ApS
CVR 42045403 · Private limited company (ApS) · Active · Low risk
AmDen Pharmaceuticals Denmark ApS is a Private limited company (ApS), founded on , based in Køge. The company is registered in the industry andre liberale, videnskabelige og tekniske tjenesteydelser i.a.n.. Our model estimates a bankruptcy risk of 0.2% over the next 12 months, which is 0.1 times the average for Danish companies. 5 annual reports have been published. The latest annual report (31 Dec 2025) shows equity of DKK 18k and a net result of DKK -4,907. CEO: Flemming Dyremose, Mikael Søndergaard Thomsen.
Bankruptcy risk for AmDen Pharmaceuticals Denmark ApS
0.1 × the average (1.41%) · higher risk than 44% of active Danish companies
Increases the risk
Reduces the risk
The factors show how often companies with the same characteristic went bankrupt compared with the average (“lift”). The risk is a statistical estimate from a model trained on 141,000+ Danish bankruptcies (AUC 0.93) – not a credit rating. Read about the method.
Company details
- CVR number
- 42045403
- Status
- Active
- Company type
- Private limited company (ApS)
- Founded
- (5 years)
- Address
- Vandværksvej 5
4600 Køge - Municipality
- Stevns
- Industry
- Andre liberale, videnskabelige og tekniske tjenesteydelser i.a.n. (749990)
Bankruptcies in the industry: Andre liberale, videnskabelige og tekniske tjenesteydelser i.a.n. - Share capital
- DKK 40k
- Auditor
- Haamann Statsautoriseret Revisionspartnerselskab
- Audit opted out
- Yes
Warning signs
| Annual reports filed late | 0 of 5 |
| Missing annual report | No |
| Negative equity | No |
| Equity ratio | 58.5% |
| Current ratio | 241% |
| Moves (last 2 years) | 0 |
| CEO changes in total | 0 |
| CEO's previous bankruptcies | 0 |
| Other companies at the address | 1 |
| Going-concern uncertainty | No |
Financials and key figures
| Financial year | 2025 | 2024 |
|---|---|---|
| Gross profit | DKK -7,514 | DKK -7,807 |
| Net profit | DKK -4,907 | DKK -7,596 |
| Equity | DKK 18k | DKK 23k |
| Total assets | DKK 31k | DKK 36k |
| Cash | DKK 10k | – |
| Short-term debt | DKK 13k | – |
| Avg. employees | 0 | – |
Latest annual report: Reporting class B · auditor's statement: Andre erklæringer uden sikkerhed · Haamann Statsautoriseret Revisionspartnerselskab.
Filed annual reports
| Reporting period | Published | Days after period end | |
|---|---|---|---|
| 1 Jan 2025 – 31 Dec 2025 | 62 | ||
| 1 Jan 2024 – 31 Dec 2024 | 42 | ||
| 1 Jan 2023 – 31 Dec 2023 | 121 | ||
| 1 Jan 2022 – 31 Dec 2022 | 117 | ||
| 15 Jan 2021 – 31 Dec 2021 | 74 |
The annual report must reach the Danish Business Authority no later than 5 months after the end of the financial year. We mark reports published more than 6 months after as “late”.
Management, owners and auditor
| Role | Name | From | To |
|---|---|---|---|
| CEO | Flemming Dyremose | Current | |
| CEO | Mikael Søndergaard Thomsen | Current | |
| Owner (50%) | Thomsen Pharma ApS | Current | |
| Owner (50%) | Flandy Holding ApS | Current | |
| Founder | Thomsen Pharma ApS | Current | |
| Founder | Flandy Holding ApS | Current |
The CEOs' other companies
Flemming Dyremose – 1 other companies
- Flandy Holding ApS Active
Mikael Søndergaard Thomsen – 7 other companies
- CONCIT PHARMA HOLDING ApS Opløst
- CONRIG PHARMA ApS Active
- CONTERA PHARMA A/S Active
- Kariya Pharmaceuticals ApS Active
- MIKAEL SØNDERGÅRD THOMSEN ApS Active
- Ousia Pharma ApS Active
- SOUND BIOTECH ApS Opløst
Address history (1 moves)
| Vandværksvej 5, 4600 Køge | |
| c/o Koncept, Naverland 2, 2., 2600 Glostrup |
Other companies at the same address
- Flandy Holding ApS Active
Similar companies in Stevns
- e-arkitekten ApS Klippinge
- opstart ApS Strøby
- Offshore Power Consulting ApS Store Heddinge
- Latus Pharma ApS Køge
- MAGLEHØJ HOLDING ApS Rødvig Stevns
- Moonlight Rødvig IVS Rødvig Stevns
- A O WIND CONSULT ApS Køge
Questions and answers about AmDen Pharmaceuticals Denmark ApS
Has AmDen Pharmaceuticals Denmark ApS gone bankrupt?
No, AmDen Pharmaceuticals Denmark ApS is not registered as bankrupt in the CVR register. Its status is: active.
What is the bankruptcy risk of AmDen Pharmaceuticals Denmark ApS?
Our model estimates a bankruptcy risk of 0.2% over the next 12 months (low risk), which is 0.1 times the average for Danish companies.
Who is the CEO of AmDen Pharmaceuticals Denmark ApS?
Flemming Dyremose, Mikael Søndergaard Thomsen are the CEOs of AmDen Pharmaceuticals Denmark ApS.
Who is the auditor of AmDen Pharmaceuticals Denmark ApS?
AmDen Pharmaceuticals Denmark ApS most recently used Haamann Statsautoriseret Revisionspartnerselskab.
When was AmDen Pharmaceuticals Denmark ApS founded?
AmDen Pharmaceuticals Denmark ApS was founded on 15 January 2021.
What is the equity of AmDen Pharmaceuticals Denmark ApS?
Equity was DKK 18k according to the annual report for the period ending 31 December 2025.
Source: the CVR register and annual reports published by the Danish Business Authority. The information is updated continuously.